Interferon-α-inducible Dendritic Cells Matured with OK-432 Exhibit TRAIL and Fas Ligand Pathway-mediated Killer Activity

Overview

Journal Sci Rep

Specialty Science

Date 2017 Feb 14

PMID 28191816

Citations 8

Authors

Terutsugu Koya

Ryu Yanagisawa

Yumiko Higuchi

Kenji Sano

Shigetaka Shimodaira

Affiliations

Soon will be listed here.

Abstract

Active human dendritic cells (DCs), which efficiently induce immune responses through their functions as antigen-presenting cells, exhibit direct anti-tumour killing activity in response to some pathogens and cytokines. These antigen-presenting and tumour killing abilities may provide a breakthrough in cancer immunotherapy. However, the mechanisms underlying this killer DC activity have not been fully proven, despite the establishment of interferon-α (IFN-α)-generated killer DCs (IFN-DCs). Here mature IFN-DCs (mIFN-DCs), generated from IFN-DCs primed with OK-432 (streptococcal preparation), exhibited elevated expression of CD86 and human leukocyte antigen-DR (minimum criteria for DC vaccine clinical trials) as well as antigen-presenting abilities comparable with those of mature IL-4-DCs (mIL-4-DCs). Interestingly, the killing activity of mIFN-DCs, which correlated with the expression of CD56 (natural killer cell marker) and was activated via the tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas ligand pathway, was stronger than that of IFN-DCs and remarkably stronger than that of mIL-4-DCs. Therefore, mIFN-DCs exhibit great potential as an anti-cancer vaccine that would promote both acquired immunity and direct tumour killing.

Citing Articles

Clinical Trial on the Safety and Tolerability of Personalized Cancer Vaccines Using Human Platelet Lysate-Induced Antigen-Presenting Cells.

Koya T, Yoshida K, Togi M, Niida Y, Togi S, Ura H Cancers (Basel). 2023; 15(14).

PMID: 37509288 PMC: 10377585. DOI: 10.3390/cancers15143627.

M cell maturation and cDC activation determine the onset of adaptive immune priming in the neonatal Peyer's patch.

Torow N, Li R, Hitch T, Mingels C, Al Bounny S, van Best N Immunity. 2023; 56(6):1220-1238.e7.

PMID: 37130522 PMC: 10262694. DOI: 10.1016/j.immuni.2023.04.002.

Identification and validation of immunotherapy for four novel clusters of colorectal cancer based on the tumor microenvironment.

Zheng X, Ma Y, Bai Y, Huang T, Lv X, Deng J Front Immunol. 2022; 13:984480.

PMID: 36389763 PMC: 9650243. DOI: 10.3389/fimmu.2022.984480.

Microbial-Derived Toll-like Receptor Agonism in Cancer Treatment and Progression.

Giurini E, Madonna M, Zloza A, Gupta K Cancers (Basel). 2022; 14(12).

PMID: 35740589 PMC: 9221178. DOI: 10.3390/cancers14122923.

GP96 and SMP30 Protein Priming of Dendritic Cell Vaccination Induces a More Potent CTL Response against Hepatoma.

Huang R, Pan J, Zhang Y, Qin Q, Chao N, Huang T J Healthc Eng. 2022; 2022:2518847.

PMID: 35070229 PMC: 8767371. DOI: 10.1155/2022/2518847.

References

Kim S, Yun C, Han S . Enhanced anti-cancer activity of human dendritic cells sensitized with gamma-irradiation-induced apoptotic colon cancer cells. Cancer Lett. 2013; 335(2):278-88. DOI: 10.1016/j.canlet.2013.02.038. View

Wolchok J, Kluger H, Callahan M, Postow M, Rizvi N, Lesokhin A . Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013; 369(2):122-33. PMC: 5698004. DOI: 10.1056/NEJMoa1302369. View

Georgopoulos N, Steele L, Thomson M, Selby P, Southgate J, Trejdosiewicz L . A novel mechanism of CD40-induced apoptosis of carcinoma cells involving TRAF3 and JNK/AP-1 activation. Cell Death Differ. 2006; 13(10):1789-801. DOI: 10.1038/sj.cdd.4401859. View

Lu G, Janjic B, Janjic J, Whiteside T, Storkus W, Vujanovic N . Innate direct anticancer effector function of human immature dendritic cells. II. Role of TNF, lymphotoxin-alpha(1)beta(2), Fas ligand, and TNF-related apoptosis-inducing ligand. J Immunol. 2002; 168(4):1831-9. DOI: 10.4049/jimmunol.168.4.1831. View

Griffith T, Wiley S, Kubin M, Sedger L, Maliszewski C, Fanger N . Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med. 1999; 189(8):1343-54. PMC: 2193036. DOI: 10.1084/jem.189.8.1343. View

Sato M, Yoshida H, Yanagawa T, Yura Y, Urata M, Atsumi M . Effects of intradermal administration of streptococcal preparation OK-432 on interferon and natural killer cell activities in patients with oral cancer. Int J Oral Surg. 1984; 13(1):7-15. DOI: 10.1016/s0300-9785(84)80050-2. View

Butterfield L, Palucka A, Britten C, Dhodapkar M, Hakansson L, Janetzki S . Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res. 2011; 17(10):3064-76. PMC: 3096674. DOI: 10.1158/1078-0432.CCR-10-2234. View

Huang J, Tatsumi T, Pizzoferrato E, Vujanovic N, Storkus W . Nitric oxide sensitizes tumor cells to dendritic cell-mediated apoptosis, uptake, and cross-presentation. Cancer Res. 2005; 65(18):8461-70. DOI: 10.1158/0008-5472.CAN-05-0654. View

Yang R, Xu D, Zhang A, Gruber A . Immature dendritic cells kill ovarian carcinoma cells by a FAS/FASL pathway, enabling them to sensitize tumor-specific CTLs. Int J Cancer. 2001; 94(3):407-13. DOI: 10.1002/ijc.1484. View

10.

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View

11.

Tosi D, Valenti R, Cova A, Sovena G, Huber V, Pilla L . Role of cross-talk between IFN-alpha-induced monocyte-derived dendritic cells and NK cells in priming CD8+ T cell responses against human tumor antigens. J Immunol. 2004; 172(9):5363-70. DOI: 10.4049/jimmunol.172.9.5363. View

12.

Zhu H, Zhang L, Huang X, Davis J, Jacob D, Teraishi F . Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms. Mol Ther. 2004; 9(5):666-73. DOI: 10.1016/j.ymthe.2004.02.007. View

13.

Hardy A, Graham D, Shearer G, Herbeuval J . HIV turns plasmacytoid dendritic cells (pDC) into TRAIL-expressing killer pDC and down-regulates HIV coreceptors by Toll-like receptor 7-induced IFN-alpha. Proc Natl Acad Sci U S A. 2007; 104(44):17453-8. PMC: 2077277. DOI: 10.1073/pnas.0707244104. View

14.

Askenasy N, Yolcu E, Yaniv I, Shirwan H . Induction of tolerance using Fas ligand: a double-edged immunomodulator. Blood. 2004; 105(4):1396-404. DOI: 10.1182/blood-2004-06-2364. View

15.

Watanabe Y, IWA T . Clinical value of immunotherapy with the streptococcal preparation OK-432 in non-small cell lung cancer. J Biol Response Mod. 1987; 6(2):169-80. View

16.

Kikkawa F, Kawai M, Oguchi H, Kojima M, Ishikawa H, Iwata M . Randomised study of immunotherapy with OK-432 in uterine cervical carcinoma. Eur J Cancer. 1993; 29A(11):1542-6. DOI: 10.1016/0959-8049(93)90291-m. View

17.

Griffith T, Chin W, Jackson G, Lynch D, Kubin M . Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol. 1998; 161(6):2833-40. View

18.

Toda K, Shiraishi T, Hirotsu T, Fukuyama K, Mineta T, Kawaguchi S . The cytocidal activity of OK-432-activated mononuclear cells against human glioma cells is partly mediated through the Fas ligand/Fas system. Jpn J Cancer Res. 1996; 87(9):972-6. PMC: 5921210. DOI: 10.1111/j.1349-7006.1996.tb02128.x. View

19.

Pasare C, Medzhitov R . Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science. 2003; 299(5609):1033-6. DOI: 10.1126/science.1078231. View

20.

Tel J, Smits E, Anguille S, Joshi R, Figdor C, de Vries I . Human plasmacytoid dendritic cells are equipped with antigen-presenting and tumoricidal capacities. Blood. 2012; 120(19):3936-44. DOI: 10.1182/blood-2012-06-435941. View